1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
668959F9F35E83C66852576E100366940
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-integrating-medical-affairs-plan-in-pharmaceutical-new-product-planning?opendocument
18
19opendocument
2034.226.234.20
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services New Product Development New Product Planning

Integrating the Medical Affairs Plan in Pharmaceutical New Product Planning

ID: 5076


Features:

26 Info Graphics

11 Data Graphics

100+ Metrics

25+ Narratives


Pages/Slides: 50


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • SPECIAL OFFER
Leading pharmaceutical and biotech companies rely on their New Product Planning teams to help deliver effective new products in shorter time frames while minimizing development costs. The role and activities of New Product Planning (NPP) groups are critical to focusing new product development and setting the stage for a successful launch.


Medical Affairs activities such as advisory boards and thought leader identification and management are important aspects of the NPP function. This Best Practices, LLC's benchmarking study presents an overview of the NPP role in the new product development process and the timing of key NPP activities throughout the development cycle. In addition, this study provides a detailed examination of the timing and value of Medical Affairs activities. Executives and managers can use this study to inform and shape their thinking around the challenges of Medical Affairs activities for new product development.


Industries Profiled:
Pharmaceutical; Biotech; Consumer Products; Diagnostic; Health Care


Companies Profiled:
Abbott Laboratories; Sanofi-aventis; Actelion; Alcon; Astellas; Allergan; Auxilium; Almirall; Theravance; Altus Biologics; Victory; Amgen; Bayer Healthcare; Biogen Idec; Daiichi Pharmaceutical Co.; Ltd.; Eli Lilly; EMD Serono; Human Genome Sciences; Merck; Novartis; Ortho Biotech; Stiefel; Takeda Pharmaceuticals; UCB Pharma

Study Snapshot

Research was conducted through survey and interviews of 27 New Product Planning leaders from 25 different companies across the globe contributed data. Additionally, In-depth interviews were conducted with leaders from 13 of the participating companies.

Key topics include:

  • The current state of New Product Planning in pharma
  • Overview of New Product Planning activities and timing during development process
  • Review the main Medical Affairs activities carried out during the development process and drill down on their timing, intended outcomes, and value for the organization

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.